Pfizer suspends clinical trials in Russia, transfers revenues from the country to Ukraine

The pharmaceutical company Pfizer says it is discontinuing clinical trials in Russia and will completely transfer the revenues from the country to Ukraine to protest Russia’s invasion of the country. 

 

The company says that it will support all public or private initiatives condemning Russia’s actions in Ukraine.

 

The company said that the international community has implemented ‘unprecedented sanctions’ to Russia. However, for humanitarian reasons, medicines were excluded from these sanctions. 

 

“Pfizer concluded that a voluntary pause in the flow of our medicines to Russia would be in direct violation of our foundational principle of putting patients first. Ending delivery of medicines, including cancer or cardiovascular therapies, would cause significant patient suffering and potential loss of life, particularly among children and elderly people.”

 

However, the company states that maintaining the supply of medicines to Russia did not mean they would continue doing business as usual in Russia. 

 

“Today we are announcing that effective immediately Pfizer will donate all profits of our Russian subsidiary to causes that provide direct humanitarian support to the people of Ukraine. This will be in addition to all other recently announced donations from Pfizer to Ukraine. Additionally, we will no longer initiate new clinical trials in Russia, and we will stop recruiting new patients in our ongoing clinical trials in the country,” said the company.

 

Pfizer is an American company founded back in 1849.